These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33663776)

  • 21. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
    Gambacorti-Passerini C; Brümmendorf TH; Kim DW; Turkina AG; Masszi T; Assouline S; Durrant S; Kantarjian HM; Khoury HJ; Zaritskey A; Shen ZX; Jin J; Vellenga E; Pasquini R; Mathews V; Cervantes F; Besson N; Turnbull K; Leip E; Kelly V; Cortes JE
    Am J Hematol; 2014 Jul; 89(7):732-42. PubMed ID: 24711212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations.
    Forbes LR; Vogel TP; Cooper MA; Castro-Wagner J; Schussler E; Weinacht KG; Plant AS; Su HC; Allenspach EJ; Slatter M; Abinun M; Lilic D; Cunningham-Rundles C; Eckstein O; Olbrich P; Guillerman RP; Patel NC; Demirdag YY; Zerbe C; Freeman AF; Holland SM; Szabolcs P; Gennery A; Torgerson TR; Milner JD; Leiding JW
    J Allergy Clin Immunol; 2018 Nov; 142(5):1665-1669. PubMed ID: 30092289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.
    Yilmaz M; Jabbour E
    Semin Oncol; 2015 Dec; 42(6):876-86. PubMed ID: 26615132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
    Rusconi F; Piazza R; Vagge E; Gambacorti-Passerini C
    Expert Opin Pharmacother; 2014 Apr; 15(5):701-10. PubMed ID: 24479382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.
    Chuah C; Koh LP; Numbenjapon T; Zang DY; Ong KH; Do YR; Ohkura M; Ono C; Viqueira A; Cortes JE; Brümmendorf TH
    Int J Hematol; 2021 Jul; 114(1):65-78. PubMed ID: 33851349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extramedullary haematopoiesis within hepatic sinusoids of a patient with primary myelofibrosis.
    Yamazaki K; Suzuki S; Kawaguchi T
    Br J Haematol; 2022 Mar; 196(5):1130. PubMed ID: 34796484
    [No Abstract]   [Full Text] [Related]  

  • 27. Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.
    García-Gutiérrez V; Martinez-Trillos A; Lopez Lorenzo JL; Bautista G; Martin Mateos ML; Alvarez-Larrán A; Iglesias Pérez A; Romo Collado A; Fernandez A; Portero A; Cuevas B; Ruiz C; Romero E; Ortega F; Mata I; Tallón J; García Garay Mdel C; Ramirez Sánchez MJ; de Las Heras N; Giraldo P; Bobillo S; Guinea JM; Deben G; Valencia S; Sebrango A; Boqué C; Maestro B; Steegmann JL
    Am J Hematol; 2015 May; 90(5):429-33. PubMed ID: 25683327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A second-generation TKI should always be used as initial therapy for CML.
    Cortes JE
    Blood Adv; 2018 Dec; 2(24):3653-3655. PubMed ID: 30587494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinase inhibitors in chronic myelogenous leukemia.
    Quintás-Cardama A; Cortes J
    Clin Adv Hematol Oncol; 2006 May; 4(5):365-74. PubMed ID: 16728945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib.
    Redaelli S; Boschelli F; Perini P; Pirola A; Viltadi M; Gambacorti-Passerini C
    Leukemia; 2010 Jun; 24(6):1223-7. PubMed ID: 20445575
    [No Abstract]   [Full Text] [Related]  

  • 31. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
    Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D
    Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical trials in chronic myeloid leukemia.
    Saussele S; Pfirrmann M
    Curr Hematol Malig Rep; 2012 Jun; 7(2):109-15. PubMed ID: 22422549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML).
    Wolfe HR; Rein LAM
    Curr Hematol Malig Rep; 2021 Oct; 16(5):448-454. PubMed ID: 34661874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New kinase inhibitor approved for CML.
    Traynor K
    Am J Health Syst Pharm; 2012 Nov; 69(21):1846. PubMed ID: 23111662
    [No Abstract]   [Full Text] [Related]  

  • 35. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
    Cortes JE; Kim DW; Kantarjian HM; Brümmendorf TH; Dyagil I; Griskevicius L; Malhotra H; Powell C; Gogat K; Countouriotis AM; Gambacorti-Passerini C
    J Clin Oncol; 2012 Oct; 30(28):3486-92. PubMed ID: 22949154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bosutinib: Valuable therapeutic option for the Bulgarian market.
    Uzunova KH; Filipova EP; Vekov TY
    J Cancer Res Ther; 2018; 14(5):909-915. PubMed ID: 30197324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current and future status of JAK inhibitors.
    McLornan DP; Pope JE; Gotlib J; Harrison CN
    Lancet; 2021 Aug; 398(10302):803-816. PubMed ID: 34454676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The need to assess financial adverse events.
    Nastoupil LJ; Prasad V; Flowers CR
    Lancet Haematol; 2018 Nov; 5(11):e508-e509. PubMed ID: 29907551
    [No Abstract]   [Full Text] [Related]  

  • 40. COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib.
    Caradec E; Mouren D; Zrounba M; Azoulay LD; Blandin C; Ivanoff S; Levy V; Brillet PY; Nunes H; Uzunhan Y
    Respir Med Res; 2021 May; 79():100799. PubMed ID: 33242734
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.